Tender detail

Supply of Serplulimab for the B.6 drug programme

Summary

The Institute of Tuberculosis and Lung Diseases is procuring the medicinal product Serplulimab for settlement under drug programme B.6, for the treatment of small-cell and non-small-cell cancer.

Reference number
2026/BZP 00547469/01
Buyer
Instytut Gruźlicy i Chorób Płuc
Country
Poland (POL)
Procedure
Basic procedure
CPV
33670000 Medicinal products for the respiratory system
Deadline
2026-11-27
Status
Open
Contract subject
Supplies
Estimated value
Not published
Source
POL_BZP

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.